Arthritis At Home (+ On the Go)
Arthritis At Home (+ On the Go)
Should medications be tapered in patients with inflammatory arthritis who are in remission?
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this Arthritis At Home, we are sharing this year’s #CRArthritis with Ms. Alexandra Charlton, Lead Pharmacist in the Division of Rheumatology at the Cumming School of Medicine at the University of Calgary. She participated in The Great Debate at this year’s meeting arguing that medications should not be tapered in patients with inflammatory arthritis who are in remission.
Alexandra defines what it means to be in remission and describes how it is different for everyone and for each disease because different disease guidelines have different definitions of what it means to be in remission. She concludes the interview with a reminder that when considering tapering, people living with arthritis should consider their medical history, duration of disease, how difficult it was for them to get into remission, and their anxiety about medications or flare ups. A younger patient with milder disease will have a different disease experience when compared to an adult patient with more active disease.
Additional learning resources
- The Lancet Rheumatology: Tapering of disease-modifying antirheumatic drugs: An overview for daily practice
- The Journal of Rheumatology: One-year outcomes after decision aid-led tapering of advanced therapy in rheumatoid arthritis
- JointHealth™ insight - Medication reimbursement coverage in Canada: A current snapshot